NZ745065A - Methods for treatment and prophylaxis of hiv and aids - Google Patents

Methods for treatment and prophylaxis of hiv and aids

Info

Publication number
NZ745065A
NZ745065A NZ745065A NZ74506517A NZ745065A NZ 745065 A NZ745065 A NZ 745065A NZ 745065 A NZ745065 A NZ 745065A NZ 74506517 A NZ74506517 A NZ 74506517A NZ 745065 A NZ745065 A NZ 745065A
Authority
NZ
New Zealand
Prior art keywords
hiv
prophylaxis
treatment
aids
methods
Prior art date
Application number
NZ745065A
Other languages
English (en)
Inventor
Daria Hazuda
Michael D Miller
Jay A Grobler
Deborah Anne Nicoll-Griffith
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Priority to NZ784982A priority Critical patent/NZ784982B2/en
Publication of NZ745065A publication Critical patent/NZ745065A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
NZ745065A 2016-02-12 2017-02-10 Methods for treatment and prophylaxis of hiv and aids NZ745065A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ784982A NZ784982B2 (en) 2017-02-10 Methods for treatment and prophylaxis of hiv and aids

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662294576P 2016-02-12 2016-02-12
US201662297657P 2016-02-19 2016-02-19
PCT/US2017/017283 WO2017139519A1 (en) 2016-02-12 2017-02-10 Methods for treatment and prophylaxis of hiv and aids

Publications (1)

Publication Number Publication Date
NZ745065A true NZ745065A (en) 2023-11-24

Family

ID=58057333

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ745065A NZ745065A (en) 2016-02-12 2017-02-10 Methods for treatment and prophylaxis of hiv and aids

Country Status (37)

Country Link
US (4) US10537589B2 (cg-RX-API-DMAC7.html)
EP (1) EP3413897B1 (cg-RX-API-DMAC7.html)
JP (4) JP6810972B2 (cg-RX-API-DMAC7.html)
KR (4) KR20220126787A (cg-RX-API-DMAC7.html)
CN (2) CN108697727A (cg-RX-API-DMAC7.html)
AU (3) AU2017217656B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018016349A2 (cg-RX-API-DMAC7.html)
CA (1) CA3013473C (cg-RX-API-DMAC7.html)
CL (1) CL2018002150A1 (cg-RX-API-DMAC7.html)
DK (1) DK3413897T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2018000183A (cg-RX-API-DMAC7.html)
EA (1) EA201891814A1 (cg-RX-API-DMAC7.html)
ES (1) ES2953535T3 (cg-RX-API-DMAC7.html)
FI (1) FI3413897T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20217231B (cg-RX-API-DMAC7.html)
HR (1) HRP20230935T1 (cg-RX-API-DMAC7.html)
HU (1) HUE063532T2 (cg-RX-API-DMAC7.html)
IL (1) IL260874B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20170038B1 (cg-RX-API-DMAC7.html)
LT (1) LT3413897T (cg-RX-API-DMAC7.html)
MD (1) MD3413897T2 (cg-RX-API-DMAC7.html)
MX (3) MX390604B (cg-RX-API-DMAC7.html)
MY (1) MY197090A (cg-RX-API-DMAC7.html)
NI (1) NI201800083A (cg-RX-API-DMAC7.html)
NZ (1) NZ745065A (cg-RX-API-DMAC7.html)
PH (1) PH12018501712A1 (cg-RX-API-DMAC7.html)
PL (1) PL3413897T3 (cg-RX-API-DMAC7.html)
PT (1) PT3413897T (cg-RX-API-DMAC7.html)
RS (1) RS64448B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201806783WA (cg-RX-API-DMAC7.html)
SI (1) SI3413897T1 (cg-RX-API-DMAC7.html)
SV (1) SV2018005733A (cg-RX-API-DMAC7.html)
TN (1) TN2018000267A1 (cg-RX-API-DMAC7.html)
TW (3) TWI822652B (cg-RX-API-DMAC7.html)
UA (1) UA126375C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017139519A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201805073B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
CN109893536B (zh) * 2018-07-02 2021-04-27 河南真实生物科技有限公司 4’-取代核苷的晶型、制备和应用
WO2020018352A1 (en) 2018-07-17 2020-01-23 Merck Sharp & Dohme Corp. Hiv drug combination for increasing barrier against resistance
EP3897660A4 (en) * 2018-12-20 2022-09-07 Merck Sharp & Dohme Corp. NEW CRYSTALLINE FORMS OF AN NRTTI COMPOUND
MX2021008751A (es) 2019-01-25 2021-11-12 Univ Brown Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
PH12021500034A1 (en) 2019-03-06 2022-06-06 Glaxosmithkline Ip No 2 Ltd Compounds useful in hiv therapy
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
EP4358968A4 (en) * 2021-06-22 2025-05-07 Rome Therapeutics, Inc. 4-ETHINYL-3-HYDROXY-TETRAHYDROFURANYL ADENINE PHOSPHORAMIDATE AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISEASES
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2276404T3 (es) * 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
KR20110079783A (ko) 2003-02-19 2011-07-07 예일 유니버시티 항-바이러스 뉴클레오시드 유사체 및 바이러스 감염, 특히 에이치아이브이 감염의 치료방법
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
US8513205B2 (en) * 2008-04-11 2013-08-20 Yale University Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase
WO2012099630A1 (en) * 2011-01-20 2012-07-26 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
JP6768796B2 (ja) 2015-09-23 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 4’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP6934019B2 (ja) * 2016-05-12 2021-09-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ウイルス薬を送達するための薬物送達システム
EP3471829A4 (en) * 2016-06-20 2020-01-15 Merck Sharp & Dohme Corp. ACTIVE SUBSTANCE RELEASE SYSTEM FOR RELEASING VIRUZIDS
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
CN114206336A (zh) * 2019-08-13 2022-03-18 默沙东公司 用于递送抗病毒剂的药物递送系统
US20230149296A1 (en) * 2020-05-05 2023-05-18 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents and contraceptives
US20230310309A1 (en) * 2020-08-25 2023-10-05 Merck Sharp & Dohme Llc Injectable depot compositions for the delivery of antiviral agents

Also Published As

Publication number Publication date
US20250073254A1 (en) 2025-03-06
JP7559175B2 (ja) 2024-10-01
TWI822652B (zh) 2023-11-21
FI3413897T3 (fi) 2023-08-25
RS64448B1 (sr) 2023-09-29
CA3013473A1 (en) 2017-08-17
GEP20207190B (en) 2020-12-10
AU2017217656B2 (en) 2020-01-30
NI201800083A (es) 2018-10-05
JP7021314B2 (ja) 2022-02-16
MY197090A (en) 2023-05-24
JP6810972B2 (ja) 2021-01-13
MX2022002924A (es) 2022-12-15
KR20210049201A (ko) 2021-05-04
TW201731514A (zh) 2017-09-16
KR20220126787A (ko) 2022-09-16
JP2021001189A (ja) 2021-01-07
GEP20217231B (en) 2021-03-25
WO2017139519A1 (en) 2017-08-17
KR20180108815A (ko) 2018-10-04
JP2022062170A (ja) 2022-04-19
AU2022201686A1 (en) 2022-03-31
TW202417010A (zh) 2024-05-01
TWI911551B (zh) 2026-01-11
DK3413897T3 (da) 2023-09-18
LT3413897T (lt) 2023-08-25
US20220331350A1 (en) 2022-10-20
US20200101098A1 (en) 2020-04-02
JP7559175B6 (ja) 2024-10-22
CA3013473C (en) 2021-10-26
EP3413897B1 (en) 2023-06-14
EA201891814A1 (ru) 2019-01-31
JP2019504857A (ja) 2019-02-21
IL260874B2 (en) 2023-10-01
US20180055867A1 (en) 2018-03-01
MX390604B (es) 2025-03-20
AU2017217656A1 (en) 2018-08-23
AU2020202866A1 (en) 2020-05-21
IL260874A (cg-RX-API-DMAC7.html) 2018-09-20
MD3413897T2 (ro) 2023-11-30
HRP20230935T1 (hr) 2023-11-24
UA126375C2 (uk) 2022-09-28
CN108697727A (zh) 2018-10-23
ES2953535T3 (es) 2023-11-14
MX2022002925A (es) 2023-02-10
US10537589B2 (en) 2020-01-21
CL2018002150A1 (es) 2018-12-14
HUE063532T2 (hu) 2024-01-28
AU2020202866B2 (en) 2022-04-07
KR20250136420A (ko) 2025-09-16
PT3413897T (pt) 2023-08-28
SV2018005733A (es) 2018-12-14
TW202610660A (zh) 2026-03-16
NZ784982A (en) 2025-03-28
TN2018000267A1 (en) 2020-01-16
US11337991B2 (en) 2022-05-24
DOP2018000183A (es) 2018-12-31
GEAP202014873A (en) 2020-07-27
EP3413897A1 (en) 2018-12-19
BR112018016349A2 (pt) 2018-12-26
CN113509480A (zh) 2021-10-19
PL3413897T3 (pl) 2023-10-02
SI3413897T1 (sl) 2023-11-30
US12171776B2 (en) 2024-12-24
SG11201806783WA (en) 2018-09-27
MX2018009763A (es) 2018-11-29
ZA201805073B (en) 2019-05-29
PH12018501712A1 (en) 2019-05-15
HK1257347A1 (en) 2019-10-18
JP2024001206A (ja) 2024-01-09
KR102317570B1 (ko) 2021-10-25
IL260874B1 (en) 2023-06-01
AU2022201686B2 (en) 2024-08-08
JOP20170038B1 (ar) 2021-08-17

Similar Documents

Publication Publication Date Title
PH12018501712A1 (en) Methods for treatment and prophylaxis of hiv and aids
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
SA519402405B1 (ar) مركبات مثبط فيروس نقص المناعة البشري
CA2998646C (en) 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
MX388757B (es) Profármacos de éster alifático antivíricos de tenofovir.
PH12018500292A1 (en) Antiviral beta-amino acid ester phosphodiame compounds
NZ724343A (en) 4’-substituted nucleoside-derivatives as hiv reverse transcriptase inhibitors
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
NZ733174A (en) Quinazoline derivatives used to treat hiv
PH12021553180A1 (en) Inhibitors of human immunodeficiency virus replication
MY202884A (en) Compounds useful in hiv therapy
WO2018111315A8 (en) PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
WO2015017393A3 (en) Piperazine derivatives as hiv protease inhibitors
MX2021007544A (es) Nuevas formas cristalinas de un compuesto inhibidor de la translocacion de la transcriptasa inversa de nucleosidos.
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
EP4696309A3 (en) Compositions comprising darunavir, cobicistat, emtricitabine and tenofovir alafenamide for use in the treatment of hiv
MX2022001271A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
MX2021015441A (es) Formas cristalinas de cabotegravir de sodio.
MX2022001266A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
NZ784982B2 (en) Methods for treatment and prophylaxis of hiv and aids
MX2019011173A (es) Compuesto que contiene silicio para la resistencia a la infeccion por el virus de la hepatitis c.
AR107596A1 (es) Procedimientos para el tratamiento y la profilaxis de vih y sida

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: MERCK SHARP + DOHME CORP., US

Effective date: 20180823

ASS Change of ownership

Owner name: MERCK SHARP + DOHME LLC, US

Effective date: 20220916

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 FEB 2026 BY THOMSON REUTERS

Effective date: 20250103